Levonorgestrel-Ethinyl Estradiol

• Contraception (Birth Control)
• Pregnancy Prevention
• Acne Treatment (some formulations)
• Menstrual Regulation

Levonorgestrel-ethinyl estradiol is a combined oral contraceptive that pairs a synthetic progestin (levonorgestrel) with a synthetic estrogen (ethinyl estradiol). It is one of the most commonly prescribed forms of hormonal contraception in the United States and is available in a wide range of formulations, including conventional 28-day cycles and extended-cycle regimens such as Seasonale and Seasonique that produce only four scheduled withdrawal bleeds per year. Beyond pregnancy prevention, the medication is used for menstrual regulation, dysmenorrhea, treatment of acne, and management of premenstrual symptoms. Like all hormonal contraceptives, it requires individualized assessment of cardiovascular risk and patient preference.

Mechanism of Action

The contraceptive effect of levonorgestrel-ethinyl estradiol arises from three complementary actions on the female reproductive system. First and most importantly, the combined hormones suppress the hypothalamic-pituitary axis, blunting the cyclical release of gonadotropin-releasing hormone and reducing pituitary secretion of follicle-stimulating hormone and luteinizing hormone. Without the mid-cycle LH surge, the dominant follicle does not rupture and ovulation does not occur. The progestin component is the dominant driver of ovulation suppression at the doses used in combined pills.

Second, levonorgestrel thickens cervical mucus, transforming it from the thin, watery, sperm-permissive secretion of the periovulatory phase into a viscous barrier that impedes sperm penetration into the upper genital tract. Third, the combined hormones induce decidualization and atrophy of the endometrium, producing a lining that is less hospitable to implantation should fertilization somehow occur. Ethinyl estradiol contributes by stabilizing the endometrium against breakthrough bleeding, smoothing out the bleeding pattern that progestin alone tends to make irregular. Estrogen also raises sex hormone-binding globulin, which lowers free testosterone and accounts for the medication's modest improvement in androgenic skin and hair conditions. Both components are well absorbed orally; ethinyl estradiol undergoes extensive enterohepatic circulation, while levonorgestrel circulates largely bound to SHBG and albumin. Hepatic metabolism via CYP3A4 makes both hormones susceptible to drug interactions with enzyme inducers.

Clinical Use

The primary indication is prevention of pregnancy, with typical-use failure rates around 7 percent per year and perfect-use failure rates under 1 percent. The American College of Obstetricians and Gynecologists endorses combined oral contraceptives as first-line reversible contraception for healthy women without contraindications. Beyond contraception, common uses include regulation of irregular menses, reduction of menstrual blood loss in menorrhagia, treatment of moderate inflammatory acne, control of dysmenorrhea, suppression of endometriosis-related pain, management of polycystic ovary syndrome, reduction of premenstrual symptoms, and prevention of recurrent functional ovarian cysts.

Extended-cycle formulations such as Seasonale (84 active pills followed by 7 placebo pills) and Seasonique (84 active pills followed by 7 low-dose ethinyl estradiol pills) are particularly useful for women who experience severe menstrual symptoms, want fewer bleeds, or have hormone-responsive conditions such as menstrual migraine without aura or endometriosis. Choice between formulations depends on hormonal sensitivity, bleeding patterns, prior contraceptive experience, and tolerability. Alternatives include progestin-only pills (useful when estrogen is contraindicated), the contraceptive patch and ring (better for adherence-challenged users), long-acting reversible contraceptives such as IUDs and implants (highest efficacy, lowest user burden), and barrier methods. The CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, available at cdc.gov, is the authoritative reference for matching patients to methods.

How to Take It

One tablet is taken by mouth at the same time each day. Consistent timing is important — variability of more than a few hours can affect efficacy, particularly for low-dose formulations. Most 28-day packs contain 21 hormone-containing tablets followed by 7 inert or low-estrogen tablets, during which a withdrawal bleed occurs. Extended-cycle packs follow product-specific schedules. The first pack can be started on the first day of menses (Day 1 start, immediate efficacy), the first Sunday after menses begins (Sunday start, requires 7 days backup), or any day with a quick-start approach (requires 7 days backup). Pills are equally effective taken with or without food.

Missed-pill management depends on how many pills are missed and where in the cycle the lapse occurred. If one active pill is late by less than 24 hours, take it as soon as remembered and continue the pack normally — no backup needed. If one or more active pills are missed by more than 24 hours, take the most recently missed pill immediately, continue the pack, and use backup contraception for 7 days. If pills are missed during the last week of active hormones, finish the active pills and skip the placebo week to start the next pack early. Storage at room temperature in the original pack is appropriate. The first 1 to 3 cycles often bring breakthrough spotting, breast tenderness, or mild nausea; these usually subside as the body adjusts.

Monitoring and Follow-Up

Before starting a combined oral contraceptive, clinicians document blood pressure, body mass index, smoking status, age, personal and family history of venous thromboembolism, migraine pattern (with or without aura), liver disease, breast cancer, and cardiovascular disease. Pelvic and breast examinations are not required to initiate contraception, per current ACOG guidance, though age-appropriate cervical cancer screening should be maintained. Blood pressure should be rechecked within a few months of starting and at least annually thereafter; sustained elevation above 140/90 mmHg generally calls for switching methods.

No routine laboratory monitoring is needed for healthy users. Annual visits should include reassessment of efficacy, side effects, blood pressure, and any new medical conditions or medications that might create contraindications. Lipid panels, fasting glucose, and liver function tests are not routinely required but are reasonable in patients with metabolic risk factors. Patients should be counseled about warning signs using the ACHES mnemonic (Abdominal pain, Chest pain, Headache, Eye problems, Severe leg pain). Clinical guidance from acog.org is the authoritative U.S. source.

Special Populations

Women over 35 who smoke should not use combined hormonal contraceptives because of the substantial increase in cardiovascular and thromboembolic risk. Combined methods are also contraindicated in women with a history of venous thromboembolism, known thrombogenic mutations, current or prior cerebrovascular or coronary disease, complicated valvular heart disease, hypertension above 160/100 mmHg, migraine with aura, current breast cancer, severe cirrhosis, hepatic adenoma or carcinoma, less than 21 days postpartum, or 21 to 42 days postpartum with additional VTE risk factors.

During breastfeeding, progestin-only methods are generally preferred for the first 4 to 6 weeks postpartum because estrogen can reduce milk supply. Adolescents can safely use combined oral contraceptives once menarche has occurred and other contraindications are excluded. Women approaching menopause without contraindications can continue combined contraception until age 50 to 55 if desired. Patients with mild hepatic impairment can sometimes use combined methods with caution; significant hepatic impairment is a contraindication. No renal dose adjustment exists, but proteinuria or active renal disease may shift the risk-benefit assessment.

When to Contact Your Doctor

Seek emergency care immediately for sudden severe leg pain or swelling (possible deep vein thrombosis), sudden shortness of breath or sharp chest pain (possible pulmonary embolism), severe one-sided weakness, facial droop, or speech difficulty (possible stroke), severe chest pain or pressure (possible heart attack), sudden severe headache unlike previous headaches, or sudden vision changes including double vision or vision loss. Severe upper-right abdominal pain may signal a hepatic problem and warrants urgent evaluation. New onset of migraine with aura should prompt discontinuation and reassessment.

Report new persistent breakthrough bleeding, breast lumps, mood changes severe enough to interfere with daily life, jaundice, or dark urine to your clinician for review. Pregnancy that occurs despite contraceptive use should be confirmed and discussed promptly. Consult a clinician before starting any new medication, especially anticonvulsants, certain antibiotics such as rifampin, or HIV medications, since drug interactions can reduce contraceptive efficacy.

Travelers crossing time zones should keep doses on their home schedule when possible to maintain consistent timing; for trips longer than a few days, transitioning to local time gradually over several days is acceptable. Bouts of vomiting or severe diarrhea within 3 to 4 hours of taking a pill may reduce absorption enough to require treating the dose as missed and using backup contraception per the missed-pill rules. Women who develop new severe headaches, particularly migraines that now include visual aura or neurologic symptoms, should stop the pill and seek evaluation rather than attempting to push through. Annual cardiovascular risk reassessment becomes especially important in the perimenopausal years.

For questions about whether levonorgestrel-ethinyl estradiol is the right contraceptive choice for you, contact us or schedule a visit with the Zimmer Medical Group team for a personalized discussion of options.